QSP Toolbox: Computational Implementation of Integrated Workflow Components for Deploying Multi-Scale Mechanistic Models

Quantitative systems pharmacology (QSP) modeling has become increasingly important in pharmaceutical research and development, and is a powerful tool to gain mechanistic insights into the complex dynamics of biological systems in response to drug treatment. However, even once a suitable mathematical framework to describe the pathophysiology and mechanisms of interest is established, final model calibration and the exploration of variability can be challenging and time consuming. QSP models are often formulated as multi-scale, multi-compartment nonlinear systems of ordinary differential equations. Commonly accepted modeling strategies, workflows, and tools have promise to greatly improve the efficiency of QSP methods and improve productivity. In this paper, we present the QSP Toolbox, a set of functions, structure array conventions, and class definitions that computationally implement critical elements of QSP workflows including data integration, model calibration, and variability exploration. We present the application of the toolbox to an ordinary differential equations-based model for antibody drug conjugates. As opposed to a single stepwise reference model calibration, the toolbox also facilitates simultaneous parameter optimization and variation across multiple in vitro, in vivo, and clinical assays to more comprehensively generate alternate mechanistic hypotheses that are in quantitative agreement with available data. The toolbox also includes scripts for developing and applying virtual populations to mechanistic exploration of biomarkers and efficacy. We anticipate that the QSP Toolbox will be a useful resource that will facilitate implementation, evaluation, and sharing of new methodologies in a common framework that will greatly benefit the community.

[1]  S. Visser,et al.  Implementation of Quantitative and Systems Pharmacology in Large Pharma , 2014, CPT: pharmacometrics & systems pharmacology.

[2]  M. J. Moné,et al.  Modeling and Simulation Tools: From Systems Biology to Systems Medicine. , 2016, Methods in molecular biology.

[3]  Ravi Iyengar,et al.  Quantitative and Systems Pharmacology in the Post-genomic Era : New Approaches to Discovering Drugs and Understanding Therapeutic , 2011 .

[4]  Henning Schmidt,et al.  Enhancing population pharmacokinetic modeling efficiency and quality using an integrated workflow , 2014, Journal of Pharmacokinetics and Pharmacodynamics.

[5]  J. Lucas,et al.  A Priori Prediction of Tumor Payload Concentrations: Preclinical Case Study with an Auristatin-Based Anti-5T4 Antibody-Drug Conjugate , 2014, The AAPS Journal.

[6]  Neil Benson,et al.  Systems Pharmacology: Bridging Systems Biology and Pharmacokinetics-Pharmacodynamics (PKPD) in Drug Discovery and Development , 2011, Pharmaceutical Research.

[7]  Willy Bauwens,et al.  Optimising the convergence of a Sobol’ sensitivity analysis for an environmental model: application of an appropriate estimate for the square of the expectation value and the total variance , 2012 .

[8]  L. Weiner,et al.  Beyond peptides and mAbs—current status and future perspectives for biotherapeutics with novel constructs , 2015, Journal of clinical pharmacology.

[9]  Ronan M. T. Fleming,et al.  Quantitative prediction of cellular metabolism with constraint-based models: the COBRA Toolbox v2.0 , 2007, Nature Protocols.

[10]  S. Sadekar,et al.  Antibody Drug Conjugates: Application of Quantitative Pharmacology in Modality Design and Target Selection , 2015, The AAPS Journal.

[11]  Stephan Schmidt,et al.  Coping with time scales in disease systems analysis: application to bone remodeling , 2011, Journal of Pharmacokinetics and Pharmacodynamics.

[12]  Francesco Pozzi,et al.  Exponential smoothing weighted correlations , 2012 .

[13]  Jerzy W. Jaromczyk,et al.  Using HPC for teaching and learning bioinformatics software: Benefits and challenges , 2013, BMC Bioinformatics.

[14]  H. Vezina,et al.  Nonclinical Pharmacology and Mechanistic Modeling of Antibody–Drug Conjugates in Support of Human Clinical Trials , 2016 .

[15]  B. Agoram,et al.  Evaluating Systems Pharmacology Models Is Different From Evaluating Standard Pharmacokinetic–Pharmacodynamic Models , 2014, CPT: pharmacometrics & systems pharmacology.

[16]  S. Marshall,et al.  Good Practices in Model‐Informed Drug Discovery and Development: Practice, Application, and Documentation , 2016, CPT: pharmacometrics & systems pharmacology.

[17]  Stephen C. Ekker,et al.  Mojo Hand, a TALEN design tool for genome editing applications , 2013, BMC Bioinformatics.

[18]  E. Diamandis,et al.  Strategies for discovering novel cancer biomarkers through utilization of emerging technologies , 2008, Nature Clinical Practice Oncology.

[19]  David J. Klinke,et al.  Integrating Epidemiological Data into a Mechanistic Model of Type 2 Diabetes: Validating the Prevalence of Virtual Patients , 2008, Annals of Biomedical Engineering.

[20]  M. Birtwistle,et al.  A General Network Pharmacodynamic Model–Based Design Pipeline for Customized Cancer Therapy Applied to the VEGFR Pathway , 2014, CPT: pharmacometrics & systems pharmacology.

[21]  K Gadkar,et al.  A Six‐Stage Workflow for Robust Application of Systems Pharmacology , 2016, CPT: pharmacometrics & systems pharmacology.

[22]  I. Pastan,et al.  Antigen shedding may improve efficiencies for delivery of antibody-based anticancer agents in solid tumors. , 2012, Cancer research.

[23]  John D. Davis,et al.  A Mechanistic Systems Pharmacology Model for Prediction of LDL Cholesterol Lowering by PCSK9 Antagonism in Human Dyslipidemic Populations , 2014, CPT: pharmacometrics & systems pharmacology.

[24]  Albert Wang,et al.  Virtual Systems Pharmacology (ViSP) software for simulation from mechanistic systems-level models , 2014, Front. Pharmacol..

[25]  Paul Polakis,et al.  Site-specific antibody drug conjugates for cancer therapy , 2013, mAbs.

[26]  Aman P. Singh,et al.  Evolution of Antibody-Drug Conjugate Tumor Disposition Model to Predict Preclinical Tumor Pharmacokinetics of Trastuzumab-Emtansine (T-DM1) , 2016, The AAPS Journal.

[27]  Gabriel Helmlinger,et al.  A Mechanistic Tumor Penetration Model to Guide Antibody Drug Conjugate Design , 2015, PloS one.

[28]  Intawat Nookaew,et al.  The RAVEN Toolbox and Its Use for Generating a Genome-scale Metabolic Model for Penicillium chrysogenum , 2013, PLoS Comput. Biol..

[29]  P Vicini,et al.  A Mechanistic, Multiscale Mathematical Model of Immunogenicity for Therapeutic Proteins: Part 1—Theoretical Model , 2014, CPT: pharmacometrics & systems pharmacology.

[30]  Hans Othmer,et al.  A Model for Direction Sensing in Dictyostelium discoideum: Ras Activity and Symmetry Breaking Driven by a Gβγ-Mediated, Gα2-Ric8 -- Dependent Signal Transduction Network , 2015, PLoS Comput. Biol..

[31]  Christina Peters,et al.  Antibody–drug conjugates as novel anti-cancer chemotherapeutics , 2015, Bioscience reports.

[32]  MN Trame,et al.  Sobol Sensitivity Analysis: A Tool to Guide the Development and Evaluation of Systems Pharmacology Models , 2015, CPT: pharmacometrics & systems pharmacology.

[33]  F Mentré,et al.  Best Practices in Population Modeling Should Always Be Evolving , 2013, CPT: pharmacometrics & systems pharmacology.

[34]  P. Lyster,et al.  NIH Support for the Emergence of Quantitative and Systems Pharmacology , 2013, CPT: pharmacometrics & systems pharmacology.

[35]  D. Lauffenburger,et al.  Receptors: Models for Binding, Trafficking, and Signaling , 1993 .

[36]  T. R. Johnson,et al.  Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin , 2016, The AAPS Journal.

[37]  A. Saltelli,et al.  Making best use of model evaluations to compute sensitivity indices , 2002 .

[38]  Richard J. Allen,et al.  Efficient Generation and Selection of Virtual Populations in Quantitative Systems Pharmacology Models , 2015 .

[39]  P. Shannon,et al.  Cytoscape: a software environment for integrated models of biomolecular interaction networks. , 2003, Genome research.

[40]  David Schrama,et al.  Antibody targeted drugs as cancer therapeutics , 2006, Nature Reviews Drug Discovery.

[41]  Dhaval K. Shah,et al.  Bench to bedside translation of antibody drug conjugates using a multiscale mechanistic PK/PD model: a case study with brentuximab-vedotin , 2012, Journal of Pharmacokinetics and Pharmacodynamics.

[42]  MC Peterson,et al.  FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment? , 2015, CPT: pharmacometrics & systems pharmacology.

[43]  CM Friedrich,et al.  A model qualification method for mechanistic physiological QSP models to support model‐informed drug development , 2016, CPT: pharmacometrics & systems pharmacology.

[44]  Christopher R. Myers,et al.  Universally Sloppy Parameter Sensitivities in Systems Biology Models , 2007, PLoS Comput. Biol..

[45]  Fergal P. Casey,et al.  Alternate virtual populations elucidate the type I interferon signature predictive of the response to rituximab in rheumatoid arthritis , 2013, BMC Bioinformatics.

[46]  K. Gadkar,et al.  Mechanism-Based Pharmacokinetic/Pharmacodynamic Model for THIOMAB™ Drug Conjugates , 2014, Pharmaceutical Research.

[47]  Jason A. Papin,et al.  Mechanistic systems modeling to guide drug discovery and development. , 2013, Drug discovery today.

[48]  DA Lauffenburger,et al.  GPS for QSP: A Summary of the ACoP6 Symposium on Quantitative Systems Pharmacology and a Stage for Near‐Term Efforts in the Field , 2016, CPT: pharmacometrics & systems pharmacology.

[49]  E. Somersalo,et al.  The Metabolism of Neurons and Astrocytes Through Mathematical Models , 2012, Annals of Biomedical Engineering.

[50]  M. Jamei,et al.  Evaluating the efficiency of payload delivery by ADCs using a minimal PBPK model , 2015 .

[51]  Saltelli Andrea,et al.  Global Sensitivity Analysis: The Primer , 2008 .

[52]  Michael M. Schmidt,et al.  A modeling analysis of the effects of molecular size and binding affinity on tumor targeting , 2009, Molecular Cancer Therapeutics.

[53]  Greg M Thurber,et al.  A mechanistic compartmental model for total antibody uptake in tumors. , 2012, Journal of theoretical biology.

[54]  Byungkook Lee,et al.  Modeling Recombinant Immunotoxin Efficacies in Solid Tumors , 2008, Annals of Biomedical Engineering.

[55]  Robert J. Neely,et al.  An integrated multiplatform bioanalytical strategy for antibody-drug conjugates: a novel case study. , 2015, Bioanalysis.

[56]  R. Iyengar,et al.  Merging Systems Biology with Pharmacodynamics , 2012, Science Translational Medicine.

[57]  A. Scott,et al.  Antibody–Drug Conjugates for Cancer Therapy , 2016, Biomedicines.

[58]  Tarek A. Leil,et al.  Quantitative Systems Pharmacology can reduce attrition and improve productivity in pharmaceutical research and development , 2014, Front. Pharmacol..

[59]  Laurent Ducry,et al.  Antibody-drug conjugates: linking cytotoxic payloads to monoclonal antibodies. , 2010, Bioconjugate chemistry.

[60]  A. Tolcher,et al.  A phase II study of IMGN242 (huC242-DM4) in patients with CanAg-positive gastric or gastroesophageal (GE) junction cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[61]  B J Schmidt,et al.  Systems Biology for Simulating Patient Physiology During the Postgenomic Era of Medicine , 2014, CPT: pharmacometrics & systems pharmacology.

[62]  Joshua A. Lerman,et al.  COBRApy: COnstraints-Based Reconstruction and Analysis for Python , 2013, BMC Systems Biology.

[63]  K. Gadkar,et al.  Development and Translational Application of an Integrated, Mechanistic Model of Antibody-Drug Conjugate Pharmacokinetics , 2016, The AAPS Journal.

[64]  M. Mavrovouniotis,et al.  Simplification of Mathematical Models of Chemical Reaction Systems. , 1998, Chemical reviews.